(Solution) - Carlisle Enterprises a specialty pharmaceutical manufacturer h -(2025 Original AI-Free Solution)

Paper Details

Carlisle Enterprises, a specialty pharmaceutical manufacturer, has been losing market share for three years because several key patents have expired. Free cash flow to the firm is expected to decline rapidly as more competitive generic drugs enter the market. Projected cash flows for the next 5 years are $8.5 million, $7 million, $5 million, $2 million, and $0.5 million. Cash flow after the fifth year is expected to be negligible. The firm?s board has decided to sell the firm to a larger pharmaceutical company that is interested in using Carlisle?s product offering to fill gaps in its own product line until it can develop similar drugs. Carlisle?s WACC is 15%. What purchase price must Carlisle obtain to earn its cost of capital?